Upload
PPT-Figure 5 Figure 5. Viral RNA titers and infectivity of intestinal contents of (A) chicks

PPT-Figure 5 Figure 5. Viral RNA titers and infectivity of intestinal contents of (A) chicks

Author : carla | Published Date : 2023-07-27

Boley PA Alhamo MA Lossie G Yadav K VasquezLee M Saif LJ et al Porcine Deltacoronavirus Infection and Transmission in Poultry United States Emerg Infect Dis 2020262255265

represent contents intestine transmission dpi equivalent genomic inoculum tcid50 porcine poultry infection infectivity viral

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Figure 5 Figure 5. Viral RNA titers and ..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Figure 5 Figure 5. Viral RNA titers and infectivity of intestinal contents of (A) chicks: Transcript

Boley PA Alhamo MA Lossie G Yadav K VasquezLee M Saif LJ et al Porcine Deltacoronavirus Infection and Transmission in Poultry United States Emerg Infect Dis 2020262255265 httpsdoiorg103201eid2602190346. -1- Figure 1 -2- Figure 3 Figure 4 Figure 5loss resistance is zero, and that the radiation resistance is the textbook figure of 35 ohms. The feedpointimpedance would then be 15+0+35 = 50 ohms, and th Schematic. of . picornavirus. . genome. . organization. . The positive-. strand. RNA has the viral . protein. . VPg. . covalently. . linked. to the 5′ end of the . genome. . . Both. the 5′ and 3′ . Figure S2. (d). (c). Figure S2.. Distribution of the 427 bacterial strains isolated from donor 1 by intestinal section and region. Percentages represent total counts from the 3 media used: MRS, Rich Media and Thioglycolate. . AGENTS. . THAT. . INACTIVATE. . VIRUS INFECTIVITY. . 1. . Physical. . agents. . . 1.a. . Temperature. All. . infective. . viruses. . lose. . infectivity. . over. . time,. . Harvala H, McIntyre CL, Imai N, Clasper L, Djoko CF, LeBreton M, et al. High Seroprevalence of Enterovirus Infections in Apes and Old World Monkeys. Emerg Infect Dis. 2012;18(2):283-286. https://doi.org/10.3201/eid1802.111363. Duh D, Saksida A, Petrovec M, Ahmeti S, Dedushaj I, Panning M, et al. Viral Load as Predictor of Crimean-Congo Hemorrhagic Fever Outcome. Emerg Infect Dis. 2007;13(11):1769-1772. https://doi.org/10.3201/eid1311.070222. Chan M, Lee N, Chan P, To K, Wong R, Ho W, et al. Seasonal Influenza A Virus in Feces of Hospitalized Adults. Emerg Infect Dis. 2011;17(11):2038-2042. https://doi.org/10.3201/eid1711.110205. Dietz K, Raddatz G, Wallis J, Müller N, Zerr I, Duerr H, et al. Blood Transfusion and Spread of Variant Creutzfeldt-Jakob Disease. Emerg Infect Dis. 2007;13(1):89. https://doi.org/10.3201/eid1301.060396. Guo L, Zhang X, Ren L, Yu X, Chen L, Zhou H, et al. Human Antibody Responses to Avian Influenza A(H7N9) Virus, 2013. Emerg Infect Dis. 2014;20(2):192-200. https://doi.org/10.3201/eid2002.131094. Temperton NJ, Chan PK, Simmons G, Zambon MC, Tedder RS, Takeuchi Y, et al. Longitudinally Profiling Neutralizing Antibody Response to SARS Coronavirus with Pseudotypes. Emerg Infect Dis. 2005;11(3):411-416. https://doi.org/10.3201/eid1103.040906. .. Blue line = cut-off; ODr - Optical Density ratio.. Serological titer (farm). Serological titer (sows). Serological titer (finishers). Figure S2.. Distribution of serological titers for . Toxoplasma gondii. Albariño CG, Foltzer M, Towner JS, Rowe LA, Campbell S, Jaramillo CM, et al. Novel Paramyxovirus Associated with Severe Acute Febrile Disease, South Sudan and Uganda, 2012. Emerg Infect Dis. 2014;20(2):211-216. https://doi.org/10.3201/eid2002.131620. Nilles EJ, de St. Aubin M, Dumas D, Duke W, Etienne M, Abdalla G, et al. Monitoring Temporal Changes in SARS-CoV-2 Spike Antibody Levels and Variant-Specific Risk for Infection, Dominican Republic, March 2021–August 2022. Emerg Infect Dis. 2023;29(4):723-733. https://doi.org/10.3201/eid2904.221628. Bai Y, Du Z, Wang L, Lau E, Fung I, Holme P, et al. Public Health Impact of Paxlovid as Treatment for COVID-19, United States. Emerg Infect Dis. 2024;30(2):262-269. https://doi.org/10.3201/eid3002.230835.

Download Document

Here is the link to download the presentation.
"Figure 5 Figure 5. Viral RNA titers and infectivity of intestinal contents of (A) chicks"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.

Related Documents

Figure 1.

Figure 1.
Figure S1 Figure S1. Phylum distribution by donor per intestinal section and region.

Figure S1 Figure S1. Phylum distribution by donor per intestinal section and region.
Survival of Infectivity

Survival of Infectivity
Figure Figure. Seroprevalence of neutralizing antibody (titers >16) to

Figure Figure. Seroprevalence of neutralizing antibody (titers >16) to
Figure Figure. Correlation between clinical outcome, serologic data, and Crimean-Congo

Figure Figure. Correlation between clinical outcome, serologic data, and Crimean-Congo
Figure 1 Figure 1. Fecal seasonal influenza A viral RNA detection rate and its

Figure 1 Figure 1. Fecal seasonal influenza A viral RNA detection rate and its
Figure 3 Figure 3. The yearly incidence of deaths for an incubation period of

Figure 3 Figure 3. The yearly incidence of deaths for an incubation period of
Figure 1 Figure 1. Serum antibodies (Abs) in patients infected with influenza A(H7N9)

Figure 1 Figure 1. Serum antibodies (Abs) in patients infected with influenza A(H7N9)
Figure 2 Figure 2. . Correlation of neutralizing antibody titers measured by plaque reduction

Figure 2 Figure 2. . Correlation of neutralizing antibody titers measured by plaque reduction
Figure S1. Distribution of SERASCA® test titers per farm (n=65 farms, finishers)

Figure S1. Distribution of SERASCA® test titers per farm (n=65 farms, finishers)
Figure 2 Figure 2. A) Organization of the viral genome of novel paramyxovirus related

Figure 2 Figure 2. A) Organization of the viral genome of novel paramyxovirus related
Figure 2 Figure 2. SARS-CoV-2 S antibody seroprevalence, titers, and vaccine doses of

Figure 2 Figure 2. SARS-CoV-2 S antibody seroprevalence, titers, and vaccine doses of
Figure 1 Figure 1. Estimated and observed viral load following treatment with placebo

Figure 1 Figure 1. Estimated and observed viral load following treatment with placebo